Global Oral Solid Dosage CDMO Market Revenue Grows at a CAGR of 6.56%.

Introduction

Straits Research released its highly anticipated report, “Global Oral Solid Dosage CDMO Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 45.98 billion in 2025 and is anticipated to grow till USD 81.17 billion by 2034, growing at a CAGR of 6.56% from 2026-2034.

Market Dynamics

The oral solid dosage CDMO market is driven by the sustained expansion of oral drug pipelines across chronic therapies, where tablets and capsules remain the preferred administration route due to dosing convenience and patient adherence. Pharmaceutical companies increasingly outsource formulation development, scale-up, and commercial manufacturing to external partners to manage portfolio breadth, accelerate timelines, and reduce fixed infrastructure burden. However, the market faces restraint from complexity associated with transferring formulations across development and manufacturing stages, particularly for modified release and high potency products, where process sensitivity and equipment variability affect reproducibility. Regulatory scrutiny across global supply chains further increases coordination challenges for sponsors and CDMOs. Despite these constraints, a strong opportunity exists in the rising demand for specialized CDMOs with expertise in controlled release technologies, containment manufacturing, and integrated packaging solutions. Growth in lifecycle management activities such as reformulations, line extensions, and regional product adaptations supports long-term outsourcing engagement, positioning oral solid dosage CDMOs as strategic partners rather than transactional manufacturers.

Market Highlights

• Product: Based on Product, the tablets segment dominated the market with a revenue share of 33.45% in 2025.
• Mechanism: Based on the Mechanism, controlled release dominated the market with a revenue share of 44.56% in 2025.
• Drug Potency: Based on Drug Potency, low-potency drugs dominated the market with a revenue share of 34.67%.
• Service: Based on Service, contract development dominated the market with a revenue share of 23.45%.
• End Use: Based on End Use, medium & small companies dominated the market with 44.56%.
• Regional Insights: North America held a dominant share of the global market, accounting for 37.54% in 2025.

Competitive Players

1. Lonza
2. Thermo Fisher Scientific Inc.
3. Cambrex Corporation
4. Catalent Inc.
5. Siegrfried Holding AG
6. Recipharm AB
7. CordenPharma International
8. Boehringer Ingelheim
9. Piramal Pharma Solutions
10. Aenova Group
11. Almac Group
12. Jubilant Pharmova Limited
13. Delpharm
14. AbbVie Contract Manufacturing
15. Next Pharma AB
16. Rubicon Research Pvt. Ltd.
17. Quotient Sciences
18. SPI Pharma
19. DPT Laboratories Ltd.
20. Alcami Corporation
21. Others

Recent Developments

February 2024: Novo Holdings announced the acquisition of Catalent Inc., a prominent CDMO in the healthcare industry. Through this acquisition, Novo Holdings gained market growth opportunities, and Catalent broadened its operational capabilities.

Segmentation

1. By Product (2026-2034)
   1. Tablets
      1. Compressed Tablets
      2. Orally Disintegrating Tablets (ODT)
      3. Chewable Tablets
      4. Bi-layer or Tri-layer Tablets
      5. Sublingual or Buccal Tablets
      6. Others
   2. Capsules
      1. Hard Gelatin Capsules
      2. Soft Gelatin Capsules
   3. Powders
   4. Granules
   5. Others
2. By Mechanism (2026-2034)
   1. Immediate Release
   2. Delayed Release
   3. Controlled Release
3. By Drug Potency (2026-2034)
   1. High Potent Drugs
   2. Moderate Potent Drugs
   3. Low Potent Drugs
4. By Service (2026-2034)
   1. Contract Development
   2. Contract Manufacturing
   3. Packaging and Labelling
   4. Regulatory Affairs
   5. Logistics & Storage
   6. Others
5. By End Use (2026-2034)
   1. Large Size Companies
   2. Medium & Small Size Companies
   3. Others